Alnylam Pharmaceuticals
ALNY
293 hedge funds and large institutions have $10.9B invested in Alnylam Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 113 increasing their positions, 84 reducing their positions, and 34 closing their positions.
41% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 34
35% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 84
4% more funds holding
Funds holding: 282 → 293 (+11)
3% more call options, than puts
Call options by funds: $109M | Put options by funds: $105M
2.28% less ownership
Funds ownership: 93.75% → 91.48% (-2.3%)
7% less capital invested
Capital invested by funds: $11.7B → $10.9B (-$796M)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$106M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$54.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43.3M |
| 5 |
O
OrbiMed
New York
|
+$41.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$456M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$35.2M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$29.4M |
| 4 |
Goldman Sachs
New York
|
-$22.8M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$15.5M |
ALNY Hedge Fund Activity: Q1 2018 in Review
293 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2018, worth a combined $10.9B — down 6.8% from $11.7B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ALNY positions and 34 closed out — a net gain of 14 holders — while 113 added to existing stakes and 84 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $106M. The largest seller was Dodge & Cox, cutting an estimated $456M.
- 293 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2018, up from 282 in Q4 2017.
- Funds reported $10.9B of Alnylam Pharmaceuticals stock for Q1 2018, down 6.8% quarter-over-quarter.
- 48 funds opened new Alnylam Pharmaceuticals positions in Q1 2018 and 34 closed out, a net change of +14 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2018 was Point72 Asset Management, an estimated $106M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2018 was Dodge & Cox, an estimated $456M sold.
Based on aggregated 13F filings for Q1 2018.